Previous issue | Volume 92 | ESPE2019

58th Annual ESPE meeting

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

Card image cap
The theme of this year’s meeting is Variety and Variation in Paediatric Endocrinology. Join us in Vienna to explore the diversity we encounter in our discipline and the care that we have to exercise when using the term “normality”. Whilst gaining an update on the latest treatments, clinical best practice and cutting edge research in the field of paediatric endocrinology.

Rapid Free Communications

Bone, Growth Plate and Mineral Metabolism Session 1

Burosumab Resulted in Better Clinical Outcomes Than Continuation with Conventional Therapy in Both Younger (1-4 Years-Old) and Older (5-12 Years-Old) Children with X-Linked Hypophosphatemia
1Johannes Kepler University Linz, Linz, Austria. 2Indiana University School of Medicine, Indianapolis, USA. 3Shriners Hospitals for Children, St. Louis, USA. 4The Children's Hospital at Westmead, Sydney, Australia. 5University of California, San Francisco, San Francisco, USA. 6University of Ottawa, Ontario, Canada. 7Karolinska Institutet, Stockholm, Sweden. 8Vanderbilt University School of Medicine, Nashville, USA. 9Royal Manchester Children's Hospital, Manchester, United Kingdom. 10Osaka Hospital, Japan Community, Healthcare Organization and Osaka University Graduate School of Medicine, Osaka, Japan. 11Seoul National University Children's Hospital, Seoul, Korea, Republic of. 12Ultragenyx Pharmaceutical Inc, Novato, USA. 13Shriners Hospital for Children-Canada, McGill University, Montreal, Canada
hrp0092rfc2.1
Does the Treatment with Recombinant Human Growth Hormone Improve Final Height in Patients Affected by X-Linked Hypophosphatemia?
1APHP, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Filiere OSCAR and Platform of expertise for rare diseases Paris-Sud, Bicêtre Paris-Sud Hospital, Le Kremlin Bicêtre, France. 2Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy. 3CHU Purpan, Department of Endocrinology, Toulouse, France. 4CHU of Besancon, Department of Pediatrics, Besançon, France
hrp0092rfc2.2
Growth Hormone Effects on Metacarpal Bone Geometry and Bone Age in Growth Hormone-Deficient Children
1University Children's Hospital, Tubingen, Germany. 2University of Witten/Herdecke, Herdecke, Germany. 3University Children's Hospital, Tubingen, Germany. 4Visiana, Hørsholm, Denmark
hrp0092rfc2.3
Bone Mass and Fracture Prevalence in Childhood Brain Cancer Survivors 2, 5 or 7 Years After Off Therapy
1Department of Pediatrics, Giannina Gaslini Institute, University of Genova, Genova, Italy. 2Department of Pediatrics, Giannina Gaslini Institute, Genova, Italy. 3Department of Neuro-oncology, Giannina Gaslini Institute, Genova, Italy
hrp0092rfc2.4
Long Term Effects of Treatment with Oxandrolone (Ox) in Addition to Growth Hormone (GH) in Girls with Turner Syndrome (TS) on Bone Mineral Density in Adulthood
1ErasmusMC, Rotterdam, Netherlands. 2Tjongerschans Ziekenhuis, Heerenveen, Netherlands. 3Amsterdam UMC, Amsterdam, Netherlands. 4UMCG, Groningen, Netherlands. 5Leiden UMC, Leiden, Netherlands. 6Radboud UMC, Nijmegen, Netherlands
hrp0092rfc2.5
Impact of Pubertal Suppression on Body Composition and Bone Mineral Density in Adolescents with Gender Dysphoria
1Developmental Endocrinology Research Group, Royal Hospital for Children, Glasgow, United Kingdom. 2Human Nutrition, University of Glasgow, Glasgow, United Kingdom
hrp0092rfc2.6